Zydus gets USFDA nod for diabetes drug Dapagliflozin
Ahemdabad: Zydus has recently announced that the company has received final approval from the US Food and Drug Administration (USFDA) to market Dapagliflozin Tablets in the strengths of 5 mg and 10 mg (USRLD: Farxiga).
Dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Dapagliflozin also lowers the risk of heart failure in adults with type 2 diabetes with heart disease.
It is also used to lower the risk of further worsening of kidney disease, end-stage kidney disease (ESKD), death due to cardiovascular disease, and hospitalization for heart failure in adults with chronic kidney disease. Dapagliflozin works by increasing the removal of sugar by kidneys.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd